EXEL Stock Analysis: Buy, Sell, or Hold?
EXEL - Exelixis Inc
$41.53
-0.83 (-1.96%)
▼
5d:
+0.63%
30d:
-6.21%
90d:
-11.08%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Distribution
EXEL is up 3.9% this week, but smart money is buying puts. Top strike: $40 2026-05-15 with 2,659 OI. Put ratio: 60% View Scanner →
Strength: 2.9/10
Get Alerted When EXEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: EXEL appears deeply undervalued. Market expects -4.6% annual earnings decline despite 84% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: EXEL appears deeply undervalued. Market expects -4.6% annual earnings decline despite 84% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$76.41
Based on 9.9% avg growth
INTRINSIC VALUE TODAY
$47.44
12.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EXEL is currently trading at $41.53, which is considered slightly low relative to its 30-day fair value range of $41.02 to $43.74. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.6) compared to its historical average (12.2). Remarkably, the market is currently pricing in an annual earnings decline of 4.6% over the next few years. This pessimistic expectation contrasts with the company's recent 84.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, EXEL is in a strong downtrend. The price is currently testing key support at $40.84. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: EXEL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $46.83 (+12.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EXEL is in a strong downtrend. The price is currently testing key support at $40.84. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: EXEL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $46.83 (+12.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$41.02 -
$43.74
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
88.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($46.83)
Fair Price Analysis
30-Day Fair Range
$41.02 -
$43.74
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$40.84
Resistance Level
$43.48
Current Trend
Strong Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.57
Wall Street Target
$46.83
(+12.8%)
Revenue Growth (YoY)
5.6%
Earnings Growth (YoY)
84.2%
Profit Margin
33.7%
Valuation Discount vs History
-4.6% cheaper
PE vs Historical
10.6 vs 12.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.6%
(market-implied from PE analysis)
1-Year Target
$39.62
(-5%)
2-Year Target
$37.80
(-9%)
3-Year Target
$36.06
(-13%)
3-Yr Target (if PE normalizes)
(PE: 11→12)
$41.62
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 15.7%)
$136.40
(+228%)
Base:
(SPY PE: 10.6, Growth: 15.7%)
$64.36
(+55%)
Bear:
(PE: 9.0, Growth: 15.7%)
$54.70
(+32%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (15x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 14.85 | Current EPS (TTM): $2.78
Bull Case
$64.17
(+55%)
Analyst growth 41.3%, PE expands to 16.3
Base Case
$58.33
(+41%)
Market implied 41.3%, PE stable at 14.9
Bear Case
$28.06
(-32%)
Severe decline -20.0%, PE contracts to 12.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.6 to 12.2
Stabilization Target:
$47.94
(+15.4%)
PE Expansion Potential:
+15.4%
Share & Embed Analysis
Last updated: March 30, 2026 8:51 AM ET
Data refreshes hourly during market hours. Next update: 9:51 AM
Data refreshes hourly during market hours. Next update: 9:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EXEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
15
Sells
Net
INSIDERS SELLING
Recent Transactions
Dana Aftab
SELL
47918 shares
2026-02-24
Dana Aftab
SELL
29873 shares
2026-02-19
Brenda Hefti
SELL
18669 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 56 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 60 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$224 | 61 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 59 HOLD |
Advanced EXEL Option Strategies
Professional options setups generated by AI based on today's EXEL price and gamma walls.
